Antipseudomonal therapy in cystic fibrosis: Aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin
- 105 Downloads
In order to determine the optimal antipseudomonal therapy in patients with cystic fibrosis aztreonam plus amikacin was compared to ceftazidime plus amikacin, and these two-week hospital regimens were followed by oral ciprofloxacin given for four weeks. Fifty-six cases of acute pulmonary exacerbation of the disease in 42 patients associated with isolation ofPseudomonas aeruginosa from the sputum were randomly treated with either aztreonam or ceftazidime (300mg/kg/day i.v.; maximum daily dose 12g) in combination with amikacin (36 mg/kg/day i.v.; maximum daily dose 1,500mg). Other aspects of the two-week treatment were constant. The two therapy groups were comparable in all respects. Both regimens were well tolerated and resulted in similar improvements in clinical, bacteriologic, radiologic and laboratory findings, and pulmonary function. Fifty patients could be reevaluated after subsequent outpatient therapy consisting of oral ciprofloxacin (30 mg/kg/day; maximum daily dose 1,500mg) given for four weeks. During this period, the clinical and laboratory improvements persisted, and the rate of eradication ofPseudomonas aeruginosa from sputum decreased from 62% to 34%. Ciprofloxacin was well tolerated and there was no drug toxicity or serious adverse effect. In the 25 prepubertal patients there was neither subjective nor objective evidence of skeletal drug toxicity. In patients with cystic fibrosis, aztreonam or ceftazidime in combination with amikacin represents an effective and safe systemic anti-pseudomonal therapy. Subsequent oral ciprofloxacin therapy for four weeks prolongs the beneficial effects and is well tolerated.
KeywordsCystic Fibrosis Ceftazidime Amikacin Drug Toxicity Aztreonam
Unable to display preview. Download preview PDF.
- 1.Høiby, N., Friis, B., Jensen, K., Koch, C., Moller, N. E., Stovring, S., Szaff, M.: Antimicrobial chemotherapy in cystic fibrosis patients. Acta Paediatrica Scandinavica 1982, Supplement 301: 75–100.Google Scholar
- 7.Wientzen, R., Prestidge, C. B., Kramer, R. I., McCracken, G. H., Nelson, J. D.: Acute pulmonary exacerbations in cystic fibrosis: a double-blind trial of tobramycin and placebo therapy. American Journal of Diseases in Children 1980, 134: 1134–1138.Google Scholar
- 20.Jones, R. N., Barry, A. L., Gavan, T. L., Washington, J. A.: Susceptibility tests: microdilution and macrodilution broth procedures. In: Lennette, E. H., Balows, A., Hausler, W. J., Shadomy, H. J. (ed.): Manual of clinical microbiology. American Society for Microbiology, Washington, DC, 1985, p. 972–977.Google Scholar
- 25.Šcribner, R. K., Marks, M. I., Weber, A. H., Tarpay, M. M., Welch, D. F.: Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates ofPseudomonas aeruginosa from patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy 1982, 21: 939–943.PubMedGoogle Scholar
- 27.Woolfrey, B. F., Fox, J. M. K., Quall, C. O., Lally, R. T.: Error rates associated with the use of recently proposed breakpoints for testingPseudomonas aeruginosa versus gentamicin, tobramycin, and amikacin by the standardized disk agar diffusion test. Antimicrobial Agents and Chemotherapy 1983, 24: 764–770.PubMedGoogle Scholar
- 28.Suter, S., Schaad, U. B., Tegner, H., Ohlsson, K., Desgrandchamps, D., Waldvogel, F. A.: Levels of free granulocyte elastase in bronchial secretions from patients with cystic fibrosis: effect of antimicrobial treatment againstPseudomonas aeruginosa. Journal of Infectious Diseases 1986, 153: 902–909.PubMedGoogle Scholar
- 30.Wolz, C., Kiosz, G., Olge, J. W., Vasil, M. L., Schaad, U. B., Botzenhart, K., Döring, G.:Pseudomonas aeruginosa cross-colonization and persistence in patients with cystic fibrosis. Use of a DNA probe. Epidemiology and Infectiology 1989, 102: 205–214.Google Scholar
- 31.Christ, W., Lehnert, T., Ulbrich, B.: Specific toxicologic aspects of the quinolones. Reviews of Infectious Diseases 1988, 10, Supplement 1: 141–146.Google Scholar